Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Kezar Life Sciences (KZR) Shares Outstanding (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Shares Outstanding for 5 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding changed 0.38% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, changed 0.38%, while the annual FY2025 figure was $7.3 million, 0.38% changed from the prior year.
  • Shares Outstanding hit $7.3 million in Q4 2025 for Kezar Life Sciences, roughly flat from $7.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $68.4 million in Q3 2022 and bottomed at $5.6 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $22.0 million, with a median of $7.3 million recorded in 2024.
  • Year-over-year, Shares Outstanding soared 41.95% in 2022 and then tumbled 89.39% in 2023.
  • Kezar Life Sciences' Shares Outstanding stood at $5.6 million in 2021, then increased by 21.74% to $6.8 million in 2022, then rose by 6.26% to $7.3 million in 2023, then rose by 0.35% to $7.3 million in 2024, then increased by 0.38% to $7.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $7.3 million, $7.3 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.